CORT - CORCEPT THERAPEUTICS INC
vs
Region: US
Website: corcept.com
Employees: 300
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the. treatment of hyperglycemia secondary to hypercortisolism in adult patients with. endogenous Cushing's syndrome.
3 Healthcare Stocks That Concern Us
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.7%. This drawdown was worse than the S&P 500’s 5.2% decline.
Read more3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth
Over the last 7 days, the United States market has risen by 2.3%, contributing to a 5.9% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment of steady growth, companies that combine robust earnings potential with significant insider ownership often stand out as promising opportunities for investors seeking alignment between management and shareholder interests.
Read moreIs Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]
Read more